BR112015008844A8 - composições e métodos relacionados a uma toxina de clostridium difficile mutante - Google Patents

composições e métodos relacionados a uma toxina de clostridium difficile mutante Download PDF

Info

Publication number
BR112015008844A8
BR112015008844A8 BR112015008844A BR112015008844A BR112015008844A8 BR 112015008844 A8 BR112015008844 A8 BR 112015008844A8 BR 112015008844 A BR112015008844 A BR 112015008844A BR 112015008844 A BR112015008844 A BR 112015008844A BR 112015008844 A8 BR112015008844 A8 BR 112015008844A8
Authority
BR
Brazil
Prior art keywords
clostridium difficile
mutant
compositions
difficile toxin
toxin
Prior art date
Application number
BR112015008844A
Other languages
English (en)
Other versions
BR112015008844B1 (pt
BR112015008844A2 (pt
Inventor
Sybil Anderson Annaliesa
Arnold Lovtin Jason
Keith Moran Justin
Ute Jansen Kathrin
K Sidhu Maninder
Edward Ruppen Mark
James Flint Michael
Kumar Kalyan Narender
G K Donald Robert
Sun Weiqiang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR122016023101-1A priority Critical patent/BR122016023101B1/pt
Application filed by Pfizer filed Critical Pfizer
Publication of BR112015008844A2 publication Critical patent/BR112015008844A2/pt
Publication of BR112015008844A8 publication Critical patent/BR112015008844A8/pt
Publication of BR112015008844B1 publication Critical patent/BR112015008844B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “composições e métodos relacionados a uma toxina de clostridium difficile mutante” em um aspecto, a invenção refere-se a uma composição imunogênica que inclui uma toxina de clostridium difficile mutante a e/ou uma toxina de clostridium difficile mutante b. a toxina mutante pode incluir um domínio glucosiltransferase tendo pelo menos uma mutação e um domínio de protease de cisteína tendo pelo menos uma mutação, relativa a toxina de c. difficile do tipo selvagem correspondente. as toxinas mutantes podem incluir pelo menos um aminoácido que é ligado em cruz quimicamente. em outro aspecto, a invenção refere-se a métodos e composições para o uso em uma cultura de clostridium difficile e na produção de toxinas de c. difficile.
BR112015008844-9A 2012-10-21 2013-10-07 Método de produção de um polipeptídeo através da cultura de clostridium difficile BR112015008844B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016023101-1A BR122016023101B1 (pt) 2012-10-21 2013-10-01 Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716605P 2012-10-21 2012-10-21
US61/716.605 2012-10-21
PCT/IB2013/059183 WO2014060898A2 (en) 2012-10-21 2013-10-07 Compositions and methods relating to a mutant clostridium difficile toxin

Publications (3)

Publication Number Publication Date
BR112015008844A2 BR112015008844A2 (pt) 2017-11-21
BR112015008844A8 true BR112015008844A8 (pt) 2018-04-03
BR112015008844B1 BR112015008844B1 (pt) 2022-03-22

Family

ID=49546596

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122016023101-1A BR122016023101B1 (pt) 2012-10-21 2013-10-01 Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
BR112015008844-9A BR112015008844B1 (pt) 2012-10-21 2013-10-07 Método de produção de um polipeptídeo através da cultura de clostridium difficile

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122016023101-1A BR122016023101B1 (pt) 2012-10-21 2013-10-01 Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Country Status (20)

Country Link
US (4) US10787652B2 (pt)
EP (2) EP3912990A1 (pt)
JP (4) JP6527661B2 (pt)
KR (5) KR101940939B1 (pt)
CN (2) CN108004286B (pt)
AU (5) AU2013333532C1 (pt)
BR (2) BR122016023101B1 (pt)
CA (2) CA3063892C (pt)
DK (1) DK2909307T3 (pt)
ES (1) ES2878551T3 (pt)
HK (2) HK1212385A1 (pt)
HR (1) HRP20211170T1 (pt)
HU (1) HUE055594T2 (pt)
IL (3) IL237792B (pt)
MX (2) MX369289B (pt)
PL (1) PL2909307T3 (pt)
PT (1) PT2909307T (pt)
RU (1) RU2630671C2 (pt)
SI (1) SI2909307T1 (pt)
WO (1) WO2014060898A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201602668VA (en) 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2968508B1 (en) 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antibodies against clostridium difficile toxins and methods of using the same
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN106801077A (zh) * 2017-02-13 2017-06-06 江南大学 一种高效杀灭滴虫等医学原虫的细菌培养上清液的制备方法和及其利用
BR112020005631A2 (pt) * 2017-09-28 2020-12-29 Pfizer Inc. Composições e métodos para eliciar uma resposta imune contra o clostridium difficile
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
CA3141165A1 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Vaccine compositions for clostridium difficile
WO2021226330A1 (en) * 2020-05-06 2021-11-11 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant
US20240189410A1 (en) 2022-12-13 2024-06-13 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4530833A (en) * 1982-09-13 1985-07-23 Wilkins Tracy D Toxins and antibodies of C. difficile
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0154064A1 (en) * 1984-03-02 1985-09-11 Tracy Dale Wilkins Toxins and antibodies of C. difficile
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
ATE161967T1 (de) 1991-04-22 1998-01-15 Massachusetts Health Res Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
EP0692974B2 (en) 1993-03-29 2007-05-30 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
MX9701683A (es) 1994-09-06 1997-06-28 Galagen Inc Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
BR9509903A (pt) 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
DE69610106D1 (de) 1995-07-07 2000-10-05 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
WO1997009886A1 (en) 1995-09-15 1997-03-20 Gerding Dale N Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
CA2264810C (en) 1996-09-30 2010-07-27 Embrex, Inc. Method of producing active immunity with vaccine conjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
AU2001261171A1 (en) 2000-05-04 2001-11-12 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
DK1397380T3 (da) 2001-06-20 2007-05-07 Univ Ramot Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
JP3991280B2 (ja) 2002-06-05 2007-10-17 中外製薬株式会社 抗体作製方法
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
US7354740B2 (en) * 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
KR101183720B1 (ko) 2004-01-16 2012-09-17 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
CA2553946C (en) * 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
JP2010522135A (ja) * 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
RU2550271C2 (ru) 2007-09-14 2015-05-10 Санофи Пастер Байолоджикс Ко. Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
WO2009132082A2 (en) 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
WO2009139919A2 (en) 2008-05-15 2009-11-19 Tufts University Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2010036826A1 (en) 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for increasing toxin production
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
KR20110100189A (ko) 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 백신 생산 방법
MY160201A (en) 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
GB0901001D0 (en) 2009-01-22 2009-03-04 Univ Nottingham Methods
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
NZ602958A (en) * 2010-03-30 2014-07-25 Pfenex Inc High level expression of recombinant toxin proteins
US8765399B2 (en) * 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
WO2012028418A1 (en) * 2010-09-02 2012-03-08 Novacem Limited Integrated process for producing compositions containing magnesium
US9598472B2 (en) * 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012078313A2 (en) 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
SG10201602668VA (en) * 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
DK3138916T3 (da) * 2011-05-27 2019-08-26 Glaxosmithkline Biologicals Sa Immunogen sammensætning
WO2012166991A1 (en) 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
US20150071958A1 (en) * 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
WO2014045226A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
CN104884081A (zh) * 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP2968508B1 (en) * 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antibodies against clostridium difficile toxins and methods of using the same
JP2016516721A (ja) * 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
WO2015061529A1 (en) * 2013-10-23 2015-04-30 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3138763A1 (en) 2015-11-17 2017-05-26 Pfizer, Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
CN117244049A (zh) * 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
BR112020005631A2 (pt) 2017-09-28 2020-12-29 Pfizer Inc. Composições e métodos para eliciar uma resposta imune contra o clostridium difficile
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Also Published As

Publication number Publication date
HRP20211170T1 (hr) 2021-11-12
KR20200017552A (ko) 2020-02-18
AU2017201193B2 (en) 2019-02-07
KR102078517B1 (ko) 2020-02-18
BR112015008844B1 (pt) 2022-03-22
US20190112584A1 (en) 2019-04-18
JP2023036952A (ja) 2023-03-14
JP2014083054A (ja) 2014-05-12
EP3912990A1 (en) 2021-11-24
AU2021277590A1 (en) 2021-12-23
US20210024903A1 (en) 2021-01-28
US20150291940A1 (en) 2015-10-15
WO2014060898A2 (en) 2014-04-24
KR20190069604A (ko) 2019-06-19
BR122016023101B1 (pt) 2022-03-22
IL284582B2 (en) 2023-04-01
US20200165582A1 (en) 2020-05-28
KR102169216B1 (ko) 2020-10-22
CN108004286B (zh) 2022-03-08
AU2019203159B2 (en) 2020-05-07
CA3063892A1 (en) 2014-04-24
PL2909307T3 (pl) 2022-11-07
KR101940939B1 (ko) 2019-01-21
AU2020203423A1 (en) 2020-06-11
US10982198B2 (en) 2021-04-20
JP7208293B2 (ja) 2023-01-18
KR20150056843A (ko) 2015-05-27
AU2019203159A1 (en) 2019-05-30
CA2887891C (en) 2023-03-07
IL237792B (en) 2021-03-25
PT2909307T (pt) 2021-07-14
EP2909307B1 (en) 2021-05-26
RU2630671C2 (ru) 2017-09-11
MX2015004986A (es) 2015-07-17
US10787652B2 (en) 2020-09-29
KR101751822B1 (ko) 2017-06-28
SI2909307T1 (sl) 2021-08-31
AU2017201193A1 (en) 2017-03-16
KR20170077263A (ko) 2017-07-05
CA2887891A1 (en) 2014-04-24
IL271064B (en) 2021-07-29
CN108004286A (zh) 2018-05-08
JP2021119775A (ja) 2021-08-19
WO2014060898A3 (en) 2014-06-12
ES2878551T3 (es) 2021-11-19
HK1212385A1 (en) 2016-06-10
AU2013333532B2 (en) 2016-11-24
IL237792A0 (en) 2015-05-31
CN104797706B (zh) 2020-05-26
US11208633B2 (en) 2021-12-28
IL271064A (en) 2020-01-30
KR20190008988A (ko) 2019-01-25
JP6871969B2 (ja) 2021-05-19
MX369289B (es) 2019-11-04
JP2019150045A (ja) 2019-09-12
HK1254448A1 (zh) 2019-07-19
AU2017201193C1 (en) 2019-10-24
KR101990272B1 (ko) 2019-06-17
CN104797706A (zh) 2015-07-22
EP2909307A2 (en) 2015-08-26
US11952597B2 (en) 2024-04-09
HUE055594T2 (hu) 2021-12-28
IL284582B (en) 2022-12-01
MX2019013075A (es) 2019-12-16
RU2015112079A (ru) 2016-12-10
AU2013333532C1 (en) 2019-10-24
BR122016023101A2 (pt) 2019-08-27
AU2013333532A1 (en) 2015-04-02
JP6527661B2 (ja) 2019-06-05
CA3063892C (en) 2023-05-09
BR112015008844A2 (pt) 2017-11-21
IL284582A (en) 2021-08-31
DK2909307T3 (da) 2021-07-05

Similar Documents

Publication Publication Date Title
BR112015008844A8 (pt) composições e métodos relacionados a uma toxina de clostridium difficile mutante
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112012028467A2 (pt) composições e métodos que compreendem variantes de subtilisina
BR112015010104A2 (pt) Variante de enzima termolisina, composição e método de limpeza
BR112014005979A2 (pt) métodos e composições para controle de erva daninha
BR112016014969A2 (pt) polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112012030179A8 (pt) Polipeptídeo contendo fc
EA201500954A1 (ru) Синергетические композиции, содержащие штамм bacillus subtilis и пестицид
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
BR112014005978A2 (pt) métodos e composições para controle de erva daninha
BR112015021269A2 (pt) peptídeos e composições para tratamento de dano articular
BR112015027757A2 (pt) elastômeros parcialmente fluorados e métodos para a produção e uso dos mesmos
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112016013194A2 (pt) Composições de higiene oral compreendendo carbonato de cálcio e sílica
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112017008595A2 (pt) composições e métodos referentes à beta-glucosidase
BR112015021147A2 (pt) métodos e detergentes enzimáticos para remoção de biomembranas
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: PFIZER INC (US)